

U.S. NUCLEAR REGULATORY COMMISSION**Date:** 08/02/2011**TELEPHONE CONVERSATION RECORD****Time:** 8:00 AM**Mail Control
or Report No(s).**

575644

License No(s). 06-19183-01**Docket No(s).** 03017101**Name of Licensee:** Boehringer Ingelheim Pharmaceuticals, Inc.**Name of Participant(s):** William Galdenzi, RSO
Dennis Lawyer, R1, DNMS**Telephone No.** 301-253-3059**Subject:** RAI, Scope of Amendment(NOTE: This will be used as the
Documents Title in ADAMS)

I asked Mr. Galdenzi for the purpose of the increase in material use whether it would change his scope or not. The main purpose was to perform a "Screen" using P-33. This would be a study for 10 weeks. This method uses robotics and has been done before with other radionuclides as well as non-radioactive materials. There would be no increase in the number of authorized uses or longer term affects to the amount of work utilizing materials. The S-35 was requested but no specific need was determined at this time but wanted to have the option for a screen using S-35 without another application request.

Action Required: Amend license**Document Availability:****Publicly Available****Non-Publicly Available** **Non-Sensitive**
 Sensitive – Privacy Act/ PII
 Immediate Release **Non-Sensitive Copyright**
 Sensitive – Internal
Normal Release Date: 8/10/2011 **Sensitive- Proprietary**
 Sensitive – Security-Related
Delayed Release Date:**SUNSI Review Completed By:** Dennis Lawyer / RA /**Document Accession #:** ML112140447